Treatment With Ruxolitinib and TAK ‐779 Enhances GII .17 Human Norovirus Replication and Enables Serial Passaging in Human Intestinal Enteroids
Genes to Cells · 2026-09 · 31 (5)
DOI: 10.1111/gtc.70139 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes to Cells, online erschienen am 01.08.2026. Verfasst von Eri Hiraishi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Testing and Technology Research, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japa…. Hauptthemen laut MEDLINE: Virus Replication, Pyrazoles, Norovirus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, Ministry of Health, Labour and Welfare.
Abstract (Originalsprache)
Human norovirus (HuNoV) is a major cause of acute viral gastroenteritis. Although it can be replicated in vitro using human intestinal enteroids (HIEs), generating high‐titer viral laboratory stocks remains challenging due to low infection and passage efficiencies. Interferon response and chemokine signaling may be key host pathways that restrict efficient HuNoV replication. Here, we evaluated the effect of their inhibitors, ruxolitinib—a Janus kinase (JAK) 1/JAK2 inhibitor—and TAK‐779—a C‐X‐C motif chemokine receptor 3 (CXCR3)/C‐C motif chemokine receptor (CCR) 5/CCR2 antagonist—on HuNoV replication in wild‐type jejunal HIEs. TAK‐779 increased GII.17 HuNoV replication by 2.3‐ and 6.0‐fold at 48 and 96 h postinfection (hpi), respectively, compared with the DMSO‐treated control. In contrast, ruxolitinib alone did not affect viral replication. Notably, simultaneous treatment with these compounds further enhanced GII.17 replication by 6.0‐ and 10.7‐fold at 48 and 96 hpi, respectively, which enabled serial passaging. These findings imply that the simultaneous suppression of these pathways potentially benefits GII.17 HuNoV replication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diagnostic Testing and Technology Research, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
- Department of Health Science, Gunma Paz University Graduate School of Health Sciences, Takasaki, Gunma, Japan.
- Department of Virology II, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
ORCID-Profile: Yoshiki Fujii, Kosuke Murakami
Förderung
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
- Ministry of Health, Labour and Welfare
Zitieren
APA
Hiraishi, E., Hayashi, T., Fujii, Y., Kimura, H., & Murakami, K. (2026). Treatment With Ruxolitinib and TAK ‐779 Enhances GII .17 Human Norovirus Replication and Enables Serial Passaging in Human Intestinal Enteroids. Genes to Cells, 31(5). https://doi.org/10.1111/gtc.70139
Vancouver
Hiraishi E, Hayashi T, Fujii Y, Kimura H, Murakami K. Treatment With Ruxolitinib and TAK ‐779 Enhances GII .17 Human Norovirus Replication and Enables Serial Passaging in Human Intestinal Enteroids. Genes to Cells. 2026;31(5). doi:10.1111/gtc.70139
BibTeX
@article{Hiraishi2026,
author = {Hiraishi, Eri and Hayashi, Tsuyoshi and Fujii, Yoshiki and Kimura, Hirokazu and Murakami, Kosuke},
title = {Treatment With Ruxolitinib and TAK ‐779 Enhances GII .17 Human Norovirus Replication and Enables Serial Passaging in Human Intestinal Enteroids},
journal = {Genes to Cells},
year = {2026},
volume = {31},
number = {5},
doi = {10.1111/gtc.70139}
}
EUVIMED